Omalizumab products (Xolair, Omlyclo) coverage
Customize your policy alerts
Sign up for Premera Bluecross Policy 5.01.513 alerts
Get alerted when Policy 5.01.513 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity, site-of-service review, and coverage criteria for omalizumab products (Xolair and Omlyclo) across indications including moderate-to-severe persistent asthma, chronic idiopathic urticaria, chronic rhinosinusitis with nasal polyps (CRSwNP), and IgE-mediated food allergy; applies to providers submitting medical or pharmacy benefit requests.
Updated initial authorization for all reviews from 6 months to 12 months.
Added Exdensur (depemokimab-ulaa) to the list of medications not to be used concurrently with omalizumab for the treatment of asthma.
Updated chronic idiopathic urticaria (CIU) dose limit to 600 mg every 2 weeks.
Updated asthma coverage criteria to use maximum tolerated doses of an inhaled corticosteroid instead of maximum doses.
Removed requirement that adults be non-smokers or enrolled in a smoking cessation program for asthma indication.
Included treatment of certain individuals with IgE-mediated food allergies in the coverage criteria.
Policy title updated from Xolair (omalizumab) to Omalizumab Products and Omlyclo (omalizumab-igec) was added with the same criteria as Xolair.
Updated chronic rhinosinusitis with nasal polyps (CRSwNP) criteria to clarify diagnostic requirements and prior systemic corticosteroid or prior surgery requirements.
Updated chronic idiopathic urticaria criteria to remove prior combination therapy requirement and added restrictions on concurrent use with Dupixent and remibrutinib (Rhapsido).
Asthma criteria updated to remove the adult non-smoker requirement and to add additional exacerbation-based diagnostic options and FEV1/FVC < 0.80 as an option.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.